People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 were associated with obesity, scientists discovered people taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)—the official name for the class of drugs—had a small reduction in risk of any of the cancers.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
